Why is SP-333 being used for OIC & not Plecanatide?
Was hoping I could get some feedback with this. With the great results from plecanatide in a large phase II in patients with CIC, why not use Plecanatide also for OIC? Seems that with both Linzness and Amitiza being used for OIC, I am confused why Plecanatide isn't and SP-333 is?
How does SP-333 differ from Plecanatide?
SP-333 is similar to Synergy’s first GC-C agonist peptide, plecanatide, except that the N- and C-terminal amino acids have been altered to reduce the potential for proteolytic degradation in the gut.
SP-333 is a modified version of Plecanatide. SP-333 will probably show results with even less diarrhea than Plecanatide. Why did Pfizer promote Celebrex and Bextra? This move will allow SGYP's GC-C drugs to gain more marketshare and make more $$. If SP-333 has less diarrhea due to it's modified structure, doesn't matter what the indications are, physicians will use it. Some of this I am speculating on, however, SP-333 is a modified Plecanatide and you can speculate the reasons behind it too.